Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in … Read more
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron. In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that … Read more
Drugmakers Roche and Sanofi’s latest earnings were largely as expected, with the companies talking up the potential of experimental medicines ahead of a looming “patent cliff” for Big Pharma. Both companies’ stocks were down less than 1% on Thursday after reporting earnings before the bell. They are both among the pharmaceutical companies that could see … Read more
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone. Top executives from drugmakers big and small told CNBC that the next phase … Read more
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images Shares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill for obesity. In … Read more
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. … Read more
Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk’s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker … Read more
Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup … Read more
LONDON — European markets edged into positive territory on Wednesday as investors take stock of the volatile year during Christmas Eve’s shortened trading session. The pan-European Stoxx 600 was just above the flatline at 9:25 a.m. in London (4:25 a.m. ET). The benchmark reached a new record closing high on Tuesday, buoyed by Copenhagen-listed Novo Nordisk’s … Read more
Shares in Novo Nordisk surged 6.9% Tuesday, after the Wegovy maker secured approval of its GLP-1 pill — a world first. The U.S. Food and Drug Administration’s approval of Novo Nordisk’s GLP-1 pill gives the Danish pharmaceutical giant a head start over U.S. rival Eli Lilly. The pill’s starting dose of 1.5 milligrams will be … Read more